ELVITEGRAVIR-COBICISTAT-EMTRICITABINE-TENOFOVIR



Genvoya


Indication:


It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product contains 4 different medications: elvitegravir, cobicistat, emtricitabine, and tenofovir. Elvitegravir is known as an integrase inhibitor. Cobicistat helps elvitegravir work better. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir is called a nucleotide reverse transcriptase inhibitor; they are often called NRTIs.



Brand name:Genvoya

Active Ingeridents:Elvitegravir-Cobicistat-Emtricitabine-Tenofovir

Company Name: Gilead

Package:30 Tablets

Strength :Elvitegravir 150mg + Cobicistat 150mg + Emtricitabine200mg +Tenofovir 10mg

Mechanism of action:


Emtricitabine:

Emtricitabine works by inhibiting reverse transcriptase, the enzyme that copies HIV RNA into new viral DNA. Emtricitabine is a synthetic nucleoside analogue of cytidine. It is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which is responsible for the inhibition of HIV-1 reverse transcriptase. It competes with the natural substrate deoxycytidine 5'-triphosphate and incorporates into nascent viral DNA, resulting in early chain termination. Therefore emtricitabine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate deoxycytidine 5'-triphosphate and by its incorporation into viral DNA. By inhibiting HIV-1 reverse transcriptase, emtricitabine can help to lower the amount of HIV, or "viral load", in a patient's body and can indirectly increase the number of immune system cells (called T cells or CD4+ T-cells). Both of these changes are associated with healthier immune systems and decreased likelihood of serious illness.

Tenofovir:

Tenofovir inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination. Specifically, the drugs are analogues of the naturally occurring deoxynucleotides needed to synthesize the viral DNA and they compete with the natural deoxynucleotides for incorporation into the growing viral DNA chain. However, unlike the natural deoxynucleotides substrates, NRTIs and NTRTIs (nucleoside/tide reverse transcriptase inhibitors) lack a 3'-hydroxyl group on the deoxyribose moiety. As a result, following incorporation of an NRTI or an NtRTI, the next incoming deoxynucleotide cannot form the next 5'-3' phosphodiester bond needed to extend the DNA chain. Thus, when an NRTI or NtRTI is incorporated, viral DNA synthesis is halted, a process known as chain termination. All NRTIs and NtRTIs are classified as competitive substrate inhibitors.

Elvitegravir

Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Integrase is an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit human topoisomerases I or II.

Cobicistat

Cobicistat is a mechanism-based inhibitor of cytochrome P450 3A (CYP3A) isoforms. Inhibition of CYP3A-mediated metabolism by cobicistat increases the systemic exposure of CYP3A substrates atazanavir and darunavir and therefore enables increased anti-viral activity at a lower dosage. Cobicistat does not have any anti-HIV activity on its own.


Dosage and Administration:


Use Genvoya (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • An extra patient leaflet is available with elvitegravir/cobicistat/emtricitabine/tenofovir. Talk to your pharmacist if you have questions about this information.

  • Take Genvoya (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir)by mouth with food.

  • Do not take an antacid that has aluminum, magnesium, or calcium in it within 2 hours before or after you take elvitegravir/cobicistat/emtricitabine/tenofovir.

  • Ask your health care provider any questions you may have about how to use elvitegravir/cobicistat/emtricitabine/tenofovir.


Side effects:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Back pain; cough; darkened skin color on the palms of the hands or soles of the feet; diarrhea; dizziness; headache; indigestion; joint pain; mild stomach pain; nausea; nose or throat irritation; runny or stuffy nose; sinus pain or drainage; strange dreams; tiredness; trouble sleeping; vomiting.


Precaution:


Before taking this medication, tell your doctor or pharmacist if you are allergic to elvitegravir, cobicistat, emtricitabine, or tenofovir; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: pancreatitis, liver problems (hepatitis B, hepatitis C, cirrhosis), alcohol use, bone problems (such as bone disease, bone loss/osteoporosis, weak/broken bones), kidney disease.


Store:


Store Genvoya (Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir) at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store in the original container away from heat, moisture, and light. Do not use if the seal on the bottle is broken or missing. Keep Genvoya (Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir) out of the reach of children and away from pets.



WARNING:


Genvoya (Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir) is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.